FDA’s Disparate Treatment Of Fibrinogen Products ‘Defies Logic,’ Octapharma Contends

 
• By Brenda Sandburg
Blood cells
US FDA sued over its classification of fibrinogen blood products • Source: Shutterstock

More from Legal & IP

More from Pink Sheet